Xibornol

Xibornol
Clinical data
AHFS/Drugs.com	International Drug Names
ATC code	J01XX02 (WHO) ;
Identifiers
	IUPAC name 4,5-dimethyl-2-[(1S,4R,6R)-1,7,7-trimethyl-6-bicyclo[2.2.1]heptanyl]phenol;
CAS Number	13741-18-9 ;
PubChem CID	11777299;
ChemSpider	9951982 ;
UNII	RQ12GMY0FZ;
KEGG	D07433 ;
ChEBI	CHEBI:131713 ;
ChEMBL	ChEMBL2104519;
CompTox Dashboard (EPA)	DTXSID60472406 ;
ECHA InfoCard	100.033.906
Chemical and physical data
Formula	C18H26O
Molar mass	258.405 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Oc1cc(c(cc1C2CC3CCC2(C)C3(C)C)C)C;
	InChI InChI=1S/C18H26O/c1-11-8-14(16(19)9-12(11)2)15-10-13-6-7-18(15,5)17(13,3)4/h8-9,13,15,19H,6-7,10H2,1-5H3 ; Key:RNRHMQWZFJXKLZ-UHFFFAOYSA-N ;
	(verify)

Xibornol is an antibiotic.

Overview

It is primarily administered to the throat.[1]

Xibornol is a lipophilic drug mainly used in Italy and Spain in spray dosage forms for the local treatment of infection and inflammation of the throat. Its poor water solubility makes difficult the development of aqueous formulations of the drug, thus giving rise to a limited number of stable and pharmaceutically accepted preparations. In fact, xibornol is actually marketed only as spray aqueous suspension. The aim of this work was to evaluate the possibility of developing a stable liquid formulation of the drug intended for oral spray administration using a self-microemulsifying drug delivery system (SMEDDS). These systems are able to adequately improve the drug solubility, allowing the introduction of relatively high concentration of drugs in the form of solution.

Labrafil M1944, Labrafil M2125 and Labrafac CC were screened as oil phases, Labrasol and Labrafac PG as surfactants and Transcutol as co-surfactant. Pseudo-ternary phase diagrams were constructed, by titration with the aqueous phase of different oil phases and surfactant/co-surfactant mixtures in order to identify the self-microemulsification region and the optimal micro-emulsion composition. Then, complete pharmaceutical formulations were prepared and evaluated for stability and viscosity properties. The final selected formulations, containing Labrafil M1944, Transcutol, Labrafac PG and a hydrophilic co-solvent (propylene glycol or PEG 200) allowed complete solubilization of the required xibornol concentration (3%, w/v) and showed physical good stability up to 2 months at 25 and 4 °C, suitable viscosity and organoleptic properties.

gollark: The same happened to me. I discovered that some languages are bad, but some others are horrifically bad.

gollark: If you accidentally write `* 2` instead of `+ 2` types won't save you.

gollark: ```haskellhaskell :: Time -> ()```

gollark: How'd they fork it to get a WebAssembly compiler, though?

gollark: So THAT'S why nobody uses other haskell compilers?

References

Cirri M, Mura P, Mora PC (2007). "Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems". Int J Pharm. 340 (1–2): 84–91. doi:10.1016/j.ijpharm.2007.03.021. PMID 17531411.

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[pmid17531411-1] Cirri M, Mura P, Mora PC (2007). "Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems". Int J Pharm. 340 (1–2): 84–91. doi:10.1016/j.ijpharm.2007.03.021. PMID 17531411.